Skip links

Publication: Imperial College London and OncoOne Unveil Latest Findings on ON104 Efficacy in Nephritis in PLoS One

We are delighted to present our latest findings in PLOS ONE, which highlight the therapeutic potential of our anti-oxMIF antibody ON104 in kidney disease!

Our findings spotlight the exciting potential of targeting oxMIF in inflammatory kidney diseases. In a rat model of crescentic glomerulonephritis (CGN), the anti-oxMIF antibody ON104 significantly reduced disease severity—improving kidney function, preserving glomerular structure, and reducing inflammation. These encouraging results on the effectiveness of ON104 offer hope for new treatment options for glomerulonephritis and related conditions.

Huge congratulations to first author Maroua FERHAT from OncoOne and special thanks to Prof. Frederick W. K. Tam and his amazing team at Imperial College London for their invaluable collaboration.

Check out the full paper here: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0311837

Home